Can Amlodipine Cause Peripheral Neuropathy?
Amlodipine is not a recognized cause of peripheral neuropathy and should not be discontinued based on neuropathy concerns alone. In fact, emerging evidence suggests amlodipine may actually have neuroprotective effects in diabetic peripheral neuropathy.
Evidence Against Amlodipine as a Neuropathy Cause
The FDA drug label for amlodipine does not list peripheral neuropathy as an adverse effect 1. The label documents expected side effects including peripheral vasodilation, hypotension, and reflex tachycardia in overdose, but makes no mention of neurotoxicity or neuropathic complications.
Recent research from 2025 demonstrates that amlodipine besylate may actually alleviate diabetic peripheral neuropathy through GPR40 receptor agonism, reducing inflammatory responses and improving mitochondrial dysfunction in peripheral nerves 2. This directly contradicts the notion that amlodipine causes neuropathy.
The Single Case Report
Only one case report from 1998 suggested a possible association between amlodipine and neuromuscular symptoms 3. This report described myopathy, myalgias, arthralgias, and facial symptoms in a single patient—but notably, these are not peripheral neuropathy. The symptoms resolved after discontinuation, but the patient was also taking zafirlukast, confounding causality. This 27-year-old case report represents the weakest form of evidence and should not drive clinical decision-making.
Actual Causes of Peripheral Neuropathy to Consider
When evaluating a patient with neuropathy on amlodipine, investigate these established causes 4:
- Diabetes (most common—affects 206 million people worldwide)
- Medications with proven neurotoxicity: chemotherapies (cisplatin, paclitaxel, vincristine), amiodarone, HIV medications (stavudine, zalcitabine)
- Vitamin B12 deficiency with elevated methylmalonic acid
- Monoclonal gammopathies
- Alcohol use
- Hereditary causes (Charcot-Marie-Tooth disease)
Recommended Diagnostic Workup
Order these initial tests 4:
- Blood glucose or HbA1c
- Serum B12 with methylmalonic acid ± homocysteine
- Serum protein electrophoresis with immunofixation
Clinical Recommendation
Do not discontinue amlodipine for peripheral neuropathy. Current hypertension guidelines specifically recommend long-acting amlodipine as a first-line calcium channel blocker 5. Switching antihypertensive therapy without clear causality risks destabilizing blood pressure control and potentially worsening cardiovascular outcomes—which directly impacts mortality and morbidity.
Instead, pursue the diagnostic workup above to identify the actual cause of neuropathy. If the patient has diabetes, optimize glycemic control as the primary intervention 6. For neuropathic pain management, use first-line agents: gabapentin (900-3600 mg/day), pregabalin (300-600 mg/day), duloxetine (60-120 mg/day), or tricyclic antidepressants like amitriptyline (25-75 mg/day) 6, 4, 7.
Common Pitfall to Avoid
Do not attribute neuropathy to amlodipine based on temporal association alone. Up to 27% of neuropathy cases have no identifiable cause even after thorough testing 4, and diabetes remains vastly underdiagnosed as a neuropathy etiology.